| answer text |
<p>Diabetes technology, blood glucose testing strips and insulin are vitally important
to many people in this country. The Department’s European Union exit contingency plans,
aim to ensure that the supply of insulin, other essential diabetes medicines and related
medical products is not disrupted in any EU exit scenario.</p><p> </p><p>Patients
can be confident in the Department’s no deal contingency plans which include sensible
mitigations for all medicines and medical products that come to the UK from or via
the EU / European Economic Area, such as precautionary stockpiling of many of those
products by suppliers.</p><p> </p><p>The Department has received very good engagement
from industry, including suppliers of insulin and related products, who share our
aims of ensuring that continuity of medicines, medical devices and clinical consumable
supplies for patients is maintained, and that suppliers are able to cope with any
potential delays at the border that may arise in the short term in the event of a
‘no deal’ EU exit. The Department is unable to provide further detail of that engagement
because, to reassure participating companies, we are committed to treating all information
received confidentially, securely and to using it only for the purposes of the Department’s
contingency programmes.</p>
|
|
